Aleon Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Aleon Pharma International is a privately held regulatory consulting firm founded in 2010, with a proven track record of over 125 successful INDs and more than 5,000 eCTD submissions. The company serves a global clientele, including publicly traded firms, across diverse therapeutic modalities such as small molecules, biologics, and cell & gene therapies. Its core business model is providing expert services to accelerate regulatory approvals with the FDA, EMA, and NMPA, operating as a revenue-generating services firm rather than a drug developer.

OncologySmall Molecules

Technology Platform

The company does not have a proprietary technology platform. Its value is based on a team of regulatory experts, including former FDA staff, and a systematized process for managing global regulatory submissions and strategy.

Opportunities

Growth is driven by increasing complexity in drug development (e.g., cell/gene therapy, mRNA) and the need for global regulatory strategy, particularly between the US and China.

The company's dual-office structure and proven track record position it to capture demand from both emerging biotechs and established pharmaceutical companies seeking specialized expertise.

Risk Factors

Key risks include dependence on retaining top-tier regulatory talent, high competition in the consulting space, and vulnerability to downturns in biopharmaceutical R&D funding.

The business model is also subject to client concentration risk if revenue relies heavily on a small number of large partners.

Competitive Landscape

Aleon competes in the regulatory affairs consulting segment against large global Contract Research Organizations (CROs), specialized boutique consulting firms, and the in-house regulatory departments of sponsor companies. Its differentiation is based on a claimed 100% IND success rate, deep expertise in US-China regulatory pathways, and a collaborative service model integrated into client teams.

More companies in Digital Health & Biotech SaaS →More companies in United States →